Regen BioPharma Inc (RGBP) Q4 2024 Earnings Report

Regen BioPharma (RGBP) reported QQ4 2024 results showing a modest top-line figure in the low six figures, but ongoing operating losses and a severely constrained liquidity position. Revenue for Q4 2024 was 59,366 USD, with gross profit of 59,366 USD and an EBITDAR of -0.503x, reflecting heavy operating and non-operating costs that drove a net loss of 167,000 USD for the quarter. The company reported negative cash flow from operations (-148,895 USD) and a minimal cash balance of 716 USD at period end, underscoring an acute liquidity risk that relies on ongoing financing activity. While gross margin is reported at 100% in the quarter (due to cost reporting, as cost of revenue equals revenue in the data), the underlying profitability metrics remain negative due to substantial SG&A and R&D spending and a sizable interest expense of 181,516 USD. The balance sheet shows negative shareholders’ equity (-5.19 million USD) and a high short-term debt burden (793,699 USD), signaling material financial leverage and limited runway absent new financing or material strategic milestones. On a year-over-year basis, revenue shows a marginal increase (0.5%), while gross profit and net income improve in magnitude but remain negative, highlighting that scale remains tiny and profitability is not in sight near term. Management commentary is not available in the provided transcript data, which limits the ability to anchor forward-looking guidance or strategic pivots. Given the current financial profile, RGBP remains a high-risk, speculative biotech investment with outsized sensitivity to equity-market access, financing terms, and any potential collaboration or licensing milestones.